Severe Neutropenia is Associated with Better Clinical Outcomes in Patients with Advanced Pancreatic Cancer Who Receive Modified FOLFIRINOX Therapy

Severe Neutropenia is Associated with Better Clinical Outcomes in Patients with Advanced Pancreatic Cancer Who Receive Modified FOLFIRINOX Therapy

While modified FOLFIRINOX therapy is effective for treating advanced pancreatic cancer, it frequently causes severe neutropenia. The present study investigated the effect of severe neutropenia on clinical outcomes in advanced pancreatic cancer patients who received modified FOLFIRINOX. The study sub...

Full description

Bibliographic Details
Main Authors: Yunami Yamada, Hironori Fujii, Daichi Watanabe, Hiroko Kato-Hayashi, Koichi Ohata, Ryo Kobayashi, Takuma Ishihara, Shinya Uemura, Takuji Iwashita, Masahito Shimizu, Akio Suzuki
Format: Article
Language:English
Published: MDPI AG 2018-11-01
Series:Cancers
Subjects:
modified FOLFIRINOX
severe neutropenia
overall survival
overall response rate
time to treatment failure
advanced pancreatic cancer
Online Access:https://www.mdpi.com/2072-6694/10/11/454

Internet

https://www.mdpi.com/2072-6694/10/11/454

Similar Items